FDA Dietary Supplement Compliance: Complete DSHEA Guide for Manufacturers 2026

The dietary supplement market in the United States is one of the most commercially significant — and most frequently misunderstood — regulatory categories for foreign manufacturers. Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), dietary supplements occupy a unique regulatory space: they are not drugs and do not require pre-market FDA approval, but they are subject to a comprehensive set of requirements that, if not met, can result in import refusals, FDA warning letters, injunctions, and product recalls. This guide covers everything foreign and domestic manufacturers need to know about FDA dietary supplement compliance in 2026.

What Is DSHEA and What Products Does It Cover?

DSHEA defines a dietary supplement as a product intended to supplement the diet that contains one or more of the following dietary ingredients: a vitamin, mineral, herb or other botanical, amino acid, dietary substance to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract, or combination of any of the above. The product must also be intended for ingestion and must be labeled as a dietary supplement.

Products that meet DSHEA's definition of a dietary supplement are regulated as a subcategory of food — not as drugs — provided they do not make drug claims. The distinction between a permissible structure-function claim and an impermissible drug claim is one of the most consequential — and most frequently violated — boundaries in dietary supplement compliance.

FDA Facility Registration and DUNS Requirements

Foreign dietary supplement manufacturers must register their facilities with the FDA under FSMA as food facilities. FDA facility registration requires a DUNS number, designates a US Agent for foreign facilities, and must be renewed biennially during October–December of even-numbered years. A dietary supplement facility without a current FDA registration cannot legally export its products to the United States.

Current Good Manufacturing Practices (cGMP) for Dietary Supplements

The most operationally significant FDA requirement for dietary supplement manufacturers is compliance with the Current Good Manufacturing Practice regulations under 21 CFR Part 111. Unlike the drug cGMP framework under 21 CFR Parts 210/211, the dietary supplement cGMP requirements are specific to the dietary supplement category and cover every aspect of manufacturing from raw material sourcing through finished product release.

Key cGMP Requirements Under 21 CFR Part 111

• Physical plant and equipment specifications — facility design, sanitation, equipment qualification, and maintenance requirements

• Qualified personnel — training requirements for all personnel involved in manufacturing, packaging, labeling, and holding dietary supplements

• Production and process controls — master manufacturing records, batch production records, and deviations documentation

• Quality control operations — incoming raw material testing, in-process controls, and finished product specifications and testing

• Laboratory operations — method validation, reference standards, equipment calibration, and out-of-specification investigation procedures

• Returned and salvaged dietary supplements — procedures for handling returned goods and determining their disposition

• Product complaints — written procedures for receiving, reviewing, and investigating consumer complaints

The FDA conducts cGMP inspections of dietary supplement facilities. Foreign facilities are subject to FDA inspection under FSMA's expanded foreign inspection authority. Facilities that fail to meet cGMP requirements receive FDA Form 483 observations and, in serious cases, warning letters that can trigger import alerts affecting all products from the facility.

New Dietary Ingredient (NDI) Notifications

One of the most frequently overlooked requirements in dietary supplement compliance is the New Dietary Ingredient (NDI) notification requirement. Under DSHEA, a dietary ingredient that was not marketed in the United States before October 15, 1994, is considered a New Dietary Ingredient. Before marketing a product containing an NDI, the manufacturer or distributor must submit a New Dietary Ingredient Notification to the FDA at least 75 days before introducing the product to the US market.

What NDI Notifications Must Include

• The name of the new dietary ingredient and a description of the ingredient

• A description of the conditions of use recommended or suggested in the product labeling

• The history of use or other evidence of safety establishing that the dietary ingredient will reasonably be expected to be safe under the conditions of use

• Copies of all studies and other evidence relied upon as the basis for the conclusion that the ingredient is safe

The FDA's review of NDI notifications is not approval — it is acknowledgment. The FDA can object to an NDI notification if the agency believes the ingredient is not reasonably expected to be safe. Many botanical ingredients, novel amino acid derivatives, and concentrated plant extracts used in supplements sold outside the US are NDIs that require notification before US market entry. Foreign manufacturers who fail to file required NDI notifications expose their products to import refusal and enforcement action.

Structure-Function Claims vs. Drug Claims

DSHEA permits dietary supplement manufacturers to make structure-function claims — statements that describe the role of a nutrient or dietary ingredient in affecting normal structure or function in humans. Examples include 'calcium builds strong bones,' 'antioxidants maintain cell integrity,' and 'fiber maintains bowel regularity.' These claims are permissible without FDA pre-approval but must be accompanied by the required disclaimer.

The Required Disclaimer

Every structure-function claim must be accompanied by the following disclaimer prominently displayed on the product label: 'This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.' This disclaimer must appear in a box, set off from other text, and in boldface type.

Claims That Cross Into Drug Territory

Certain types of claims automatically classify a product as a drug rather than a dietary supplement, regardless of how the product is formulated. These include claims that the product treats, cures, mitigates, or prevents a specific disease or condition. For example: 'reduces LDL cholesterol' is a structure-function claim; 'treats hypercholesterolemia' is a drug claim. 'Supports immune function' is permissible; 'prevents influenza' is a drug claim. Foreign manufacturers who use claims permissible in their home markets — particularly in European or Asian markets where disease claims are sometimes permitted — must review and revise all product labeling before US market entry.

Dietary Supplement Labeling Requirements

Dietary supplement labels must include a Supplement Facts panel — the dietary supplement equivalent of the Nutrition Facts label. The Supplement Facts panel must list each dietary ingredient by name, the amount per serving, and the percent Daily Value (DV) if established. Foreign manufacturers should undergo a complete label compliance review before importing any dietary supplement into the US, as labeling errors are one of the most common causes of import refusals.

Required Label Elements

• Statement of identity — the product must be labeled as a 'dietary supplement' or with a more specific descriptor (e.g., 'herbal supplement,' 'vitamin supplement')

• Net quantity of contents — expressed in both US customary and metric units

• Supplement Facts panel — listing all dietary ingredients, serving size, and servings per container

• Ingredient list — all non-dietary ingredients (excipients, fillers, binders) must be listed by their common or usual names

• Name and address of manufacturer, packer, or distributor

• Directions for use

Adverse Event Reporting for Dietary Supplements

The Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006 requires dietary supplement manufacturers and distributors to report serious adverse events associated with their products to the FDA. A serious adverse event is defined identically to the MoCRA definition: death, life-threatening conditions, inpatient hospitalization, persistent or significant disability, congenital anomaly, or any event requiring medical or surgical intervention.

Serious adverse event reports must be submitted to the FDA within 15 business days of receiving information about the event. Manufacturers and distributors must also maintain records of all adverse events — serious and non-serious — for six years.

Common FDA Compliance Failures for Dietary Supplement Manufacturers

• Selling products containing NDIs without filing the required 75-day advance notification

• Making disease claims in product labeling, advertising, or on the company website

• Failing to meet cGMP requirements — particularly for quality control testing of raw materials and finished products

• Omitting or incorrectly formatting the required structure-function claim disclaimer

• Incomplete or incorrectly formatted Supplement Facts panels

• Failure to register the manufacturing facility as a food facility under FSMA

• Exporting to the US from a facility that has not designated a US Agent

How Axentra Supports Dietary Supplement FDA Compliance

Axentra provides comprehensive dietary supplement compliance services for both foreign and domestic manufacturers. Our services include FDA facility registration and US Agent designation, NDI notification preparation and filing, label and Supplement Facts panel review, structure-function claim substantiation review, cGMP gap assessments, and adverse event reporting system setup.

Every engagement is managed by a single senior regulatory expert with deep knowledge of both DSHEA and the broader FDA regulatory framework. Contact Axentra for a free 24-hour expert assessment of your dietary supplement FDA compliance needs.